Opthea (ASX: $OPT) corporate presentation highlights

Opthea Limited (ASX: $OPT) presented its corporate update in March 2024, emphasizing the progress of sozinibercept, a potential breakthrough in addressing vision loss in patients with wet age-related macular degeneration (wet AMD). The company, with its proprietary VEGF-C/D TRAP technology, aims to improve patient outcomes and transform the treatment landscape for this high unmet medical need.

Executive commentary on sozinibercept and market potential

Opthea's CEO, Fred Guerard, highlighted the company's dedication to advancing sozinibercept to improve and protect patients' vision. The Phase 3 trials, COAST and ShORe, are near completion of enrollment, with topline data expected in mid-CY2025. The company's focus on developing a market access strategy and strengthening medical expert engagement underscores its commitment to addressing the substantial market opportunity in wet AMD treatment.

Summary of Opthea's corporate presentation and outlook

Opthea's corporate presentation showcased the potential of sozinibercept to be the first product in over 15 years to improve vision loss in wet AMD patients. With the completion of Phase 3 trial enrollment and anticipated topline data in mid-CY2025, Opthea is poised to make significant strides in addressing the high unmet need in wet AMD treatment. The company's commitment to regulatory preparations, commercial readiness, and its financial snapshot, including the Development Funding Agreement, reflects its strategic approach to advancing sozinibercept and tapping into the substantial market opportunity.